Poll: docs say don't take away CME support

Share this article:
A poll of 268 physicians found that 92% disagree with an American Medical Association (AMA) committee's call to end commercial support of CME.

Respondents to the online poll, by med ed provider Pri-Med, expressed concern that a ban on commercial support would make it more expensive for them to receive CME and that the quality of CME would decrease, making it harder for physicians to stay up to date and ultimately impacting patient care.
“I don't receive CME reimbursement from my employer,” said one respondent. “Any subsidy is very beneficial to me.”

Last month, the AMA's Council on Ethical and Judicial Affairs, which makes ethics policy for the society, issued a report arguing that physicians and institutions of medicine should not accept commercial support for CME except for narrow technical training on new diagnostic or therapeutic devices and techniques. The report's recommendations will be taken up by the AMA House of Delegates at its annual meeting, June 14-18 in Chicago.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.